GlassScriptPhysician profile
Peter K Tothy
NPI 1023157278
$26,394.98
in general payments reported to CMS, 2019-2025
86 companies · $7,596 in 2025
The $7,596 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,013 · 2020: $745 · 2021: $315 · 2022: $1,815 · 2023: $6,126 · 2024: $5,784 · 2025: $7,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $6,618 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,714.25 |
| Consulting Fee | $6,617.50 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,345.65 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,136.08 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,943.03 | 2022-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $1,272.57 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Novartis Pharmaceuticals Corporation | $1,070.90 | 2019-2025 | |
| Tosoh Bioscience, INC. | $948.00 | 2019 | |
| Pfizer INC. | $913.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $864.40 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $832.43 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $739.88 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Genentech USA, INC. | $715.90 | 2019-2025 | Venclexta, Polivy, Perjeta |
| Gilead Sciences, INC. | $569.63 | 2022-2025 | Trodelvy |
| Eisai INC. | $553.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $520.85 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Exelixis INC. | $507.17 | 2019-2025 | Cabometyx |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $474.85 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Astellas Pharma US INC | $436.11 | 2019-2025 | Xtandi, Padcev, Xospata |
| Genzyme Corporation | $411.45 | 2019-2025 | |
| Incyte Corporation | $402.84 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Abbvie INC. | $397.11 | 2019-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $354.00 | 2019-2023 | Imbruvica, Epkinly |
| Stemline Therapeutics INC. | $328.22 | 2023-2025 | Orserdu |
| Lilly USA, LLC | $261.29 | 2019-2025 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $254.68 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $251.98 | 2024-2025 | Onivyde |
| Janssen Pharmaceuticals, INC | $227.37 | 2019-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $223.03 | 2019-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $207.77 | 2019-2025 | |
| Beigene USA, INC. | $203.16 | 2023-2025 | Brukinsa, Tevimbra |
| Novocure Gmbh | $200.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $189.07 | 2019-2025 | Libtayo |
| Seagen INC. | $187.15 | 2019-2023 | Padcev, Tukysa, Tivdak |
| Galvanize Therapeutics, INC | $184.74 | 2025 | Aliya System |
| Rigel Pharmaceuticals, INC. | $177.26 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Spectrum Pharmaceuticals INC. | $174.26 | 2019 | |
| Array Biopharma INC | $148.89 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmaessentia USA Corporation | $142.24 | 2022-2025 | Besremi |
| Adc Therapeutics America, INC. | $137.98 | 2021-2025 | |
| Emd Serono, INC. | $130.49 | 2019-2025 | Tepmetko, Bavencio |
| Sobi, INC | $124.46 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.57 | 2020-2025 | Fruzaqla, Iclusig, Ninlaro |
| Sumitomo Pharma America, INC. | $108.82 | 2023-2025 | Orgovyx |
| Kite Pharma, INC. | $100.05 | 2021-2024 | Yescarta |
| Intuitive Surgical, INC. | $95.83 | 2023 | Da Vinci Surgical System |
| Deciphera Pharmaceuticals INC. | $89.22 | 2022-2025 | Qinlock, Romvimza |
| Coherus Oncology, INC. | $86.91 | 2023-2025 | Loqtorzi |
| Beone Medicines USA, INC. | $85.28 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $84.13 | 2023-2025 | Fotivda |
| Geron Corporation | $81.83 | 2024-2025 | Rytelo |
| Mirati Therapeutics, INC. | $79.96 | 2023-2024 | Krazati |
| Tesaro, INC. | $75.38 | 2019 | |
| Morphosys, US INC. | $74.45 | 2022-2024 | Monjuvi |
| Acrotech Biopharma INC. | $71.46 | 2023-2024 | Beleodaq |
| Tersera Therapeutics LLC | $65.08 | 2020-2025 | Xermelo, Zoladex |
| Agios Pharmaceuticals, INC. | $64.93 | 2023-2024 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $63.72 | 2024-2025 | Clonoseq |
| Genmab U.S., INC. | $61.68 | 2023-2024 | Epkinly |
| Recordati_rare_diseases_inc. | $60.93 | 2023-2025 | Sylvant, Enjaymo |
| Servier Pharmaceuticals LLC | $57.72 | 2023-2025 | |
| Iovance Biotherapeutics, INC. | $45.86 | 2024-2025 | Amtagvi |
| Teva Pharmaceuticals USA, INC. | $43.15 | 2019 | |
| Dendreon Pharmaceuticals LLC | $42.64 | 2019 | |
| Puma Biotechnology, INC. | $40.70 | 2019-2025 | |
| Fennec Pharmaceuticals, INC. | $40.28 | 2024 | Pedmark |
| Pharmacosmos Therapeutics INC. | $37.35 | 2025 | Monoferric |
| Apellis Pharmaceuticals, INC. | $36.09 | 2024 | Empaveli |
| Syndax Pharmaceuticals, INC. | $33.56 | 2025 | |
| Caris Mpi, INC. | $31.48 | 2025 | Mi Cancer Seek |
| Amneal Pharmaceuticals LLC | $29.61 | 2025 | Alymsys |
| Menarini Silicon Biosystems, INC. | $28.81 | 2025 | |
| Tempus Ai, INC | $28.01 | 2024 | |
| Dova Pharmaceuticals | $26.71 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $21.49 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.50 | 2024 | Givlaari |
| Global Blood Therapeutics, INC. | $20.31 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.31 | 2025 | Danziten |
| Aurobindo Pharma USA, INC. | $20.13 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.82 | 2025 | |
| Cti Biopharma Corp. | $19.42 | 2023 | Vonjo |
| Verity Pharmaceuticals INC. | $18.25 | 2023 | Trelstar |
| Immunogen, INC. | $18.01 | 2023 | Elahere |
| Amag Pharmaceuticals, INC. | $16.96 | 2019 | |
| Kyowa Kirin, INC. | $15.57 | 2019 | |
| Taiho Oncology, INC. | $15.57 | 2024 | |
| Sandoz INC. | $13.73 | 2019 | |
| Fortovia Therapeutics, INC. | $8.63 | 2019 |
Drugs and devices associated with these payments
Calquence $2,174Opdivo $654Keytruda $479Lenvima $422Xtandi $385Enhertu $363Kisqali $360Orserdu $328Reblozyl $315Cabometyx $312Venclexta $303Lynparza $282Padcev $265Imbruvica $257Pomalyst $254Trodelvy $246Orgovyx $220Brukinsa $217Talzenna $210Jakafi $209Epkinly $203Ojjaara $195Aliya System $185Jemperli $185Zejula $185Inlyta $170Comirnaty $158Krazati $154Onivyde $152Bosulif $151Ultomiris $148Sarclisa $145Pluvicto $141Libtayo $132Opdualag $130Ibrance $129Besremi $128Braftovi $128Tukysa $122Lorbrena $121Elrexfio $121Zepzelca $115Verzenio $110Nubeqa $107Xofigo $107Doptelet $107Mektovi $107Rybrevant $101Imfinzi $99.94Rezlidhia $96.76Tavalisse $96.76Da Vinci Surgical System $95.83Polivy $90.31Piqray $90.02Lutathera $87.74Fotivda $84.13Rytelo $81.83Welireg $81.36Monjuvi $79.09Darzalex $77.00Scemblix $76.83Beleodaq $71.46Tevimbra $71.32Tecvayli $69.85Qinlock $65.69Paxlovid $65.55Clonoseq $63.72Udenyca $63.21Adcetris $61.53Bavencio $57.54Jaypirca $55.89Fruzaqla $54.81Nplate $53.40Xgeva $53.40Vectibix $53.40Lumakras $53.32Injectafer $51.93Zynlonta $51.10Keytruda Qlex $48.95Amtagvi $45.86Phesgo $45.45Perjeta $45.45Tecentriq Hybreza $44.38Avastin $44.38Tecentriq $44.38Wayrilz $43.19Sylvant $42.99Romvimza $42.82Erleada $40.98Pyrukynd $40.30Pedmark $40.28Lunsumio $38.85Monoferric $37.35Xospata $36.92Enjaymo $36.55Jevtana $36.31Empaveli $36.09Elahere $34.20Gavreto $34.09Tibsovo $33.45
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Tothy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.